Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:AXLA NASDAQ:FENC NASDAQ:GMDA NASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.11$17.47$13.50▼$25.67$3.84B0.542.80 million shs3.45 million shsAXLAAxcella Health$0.40$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,782 shsFENCAdherex Technologies$8.76-3.0%$8.63$3.96▼$9.42$252.04M0.5856,200 shs40,100 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsINMBINmune Bio$2.01+2.0%$2.35$1.71▼$11.64$52.37M1.03759,153 shs472,641 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-4.51%-6.34%-22.59%-4.73%AXLAAxcella Health0.00%0.00%0.00%0.00%0.00%FENCAdherex Technologies-2.99%-2.67%-3.84%+10.47%+66.54%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%INMBINmune Bio+2.03%+3.08%-21.48%-73.90%-67.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.11$17.47$13.50▼$25.67$3.84B0.542.80 million shs3.45 million shsAXLAAxcella Health$0.40$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,782 shsFENCAdherex Technologies$8.76-3.0%$8.63$3.96▼$9.42$252.04M0.5856,200 shs40,100 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsINMBINmune Bio$2.01+2.0%$2.35$1.71▼$11.64$52.37M1.03759,153 shs472,641 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-4.51%-6.34%-22.59%-4.73%AXLAAxcella Health0.00%0.00%0.00%0.00%0.00%FENCAdherex Technologies-2.99%-2.67%-3.84%+10.47%+66.54%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%INMBINmune Bio+2.03%+3.08%-21.48%-73.90%-67.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6771.74% UpsideAXLAAxcella Health 0.00N/AN/AN/AFENCAdherex Technologies 3.00Buy$13.3352.21% UpsideGMDAGamida Cell 0.00N/AN/AN/AINMBINmune Bio 2.57Moderate Buy$18.40815.42% UpsideCurrent Analyst Ratings BreakdownLatest ADMA, GMDA, AXLA, INMB, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/15/2025FENCAdherex TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $14.007/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M9.01$0.54 per share29.76$1.48 per share10.89AXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AFENCAdherex Technologies$47.54M5.14$0.03 per share279.60($0.21) per share-41.71GMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00INMBINmune Bio$50K1,068.72N/AN/A$1.45 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8618.7323.35N/A44.06%41.01%28.47%11/6/2025 (Estimated)AXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AFENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)GMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/AINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)Latest ADMA, GMDA, AXLA, INMB, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78AXLAAxcella HealthN/A0.800.80FENCAdherex TechnologiesN/A4.854.59GMDAGamida Cell213.142.162.09INMBINmune BioN/A4.204.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AXLAAxcella Health65.07%FENCAdherex Technologies55.51%GMDAGamida Cell50.34%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%AXLAAxcella Health2.20%FENCAdherex Technologies11.76%GMDAGamida Cell3.40%INMBINmune Bio35.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million230.28 millionOptionableAXLAAxcella Health112.95 million2.88 millionOptionableFENCAdherex Technologies1027.91 million24.63 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableINMBINmune Bio1026.59 million17.09 millionOptionableADMA, GMDA, AXLA, INMB, and FENC HeadlinesRecent News About These CompaniesINmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSeptember 8, 2025 | zacks.comINmune Bio, Inc. (NASDAQ:INMB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 21, 2025 | marketbeat.comINmune Bio Inc. Stock Grades | INMB | Barron'sAugust 16, 2025 | barrons.comINmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comBTIG Reaffirms Their Hold Rating on Inmune Bio (INMB)August 10, 2025 | theglobeandmail.comIs INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?August 10, 2025 | finance.yahoo.comInmune Bio (INMB) was downgraded to a Sell Rating at ScotiabankAugust 9, 2025 | theglobeandmail.comInmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’sAugust 9, 2025 | theglobeandmail.comINmune Bio (INMB) Q2 Loss Widens 110%August 8, 2025 | aol.comAINmune Bio, Inc. (INMB) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comINmune Bio stock soars after prostate cancer trial meets endpointsAugust 4, 2025 | investing.comINmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to EnrollmentAugust 4, 2025 | finance.yahoo.comINmune Bio Shares Surge as Prostate Cancer Trial Achieves Key GoalsAugust 4, 2025 | msn.comINmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to EnrollmentAugust 4, 2025 | globenewswire.comINmune Bio options imply 14.9% move in share price post-earningsAugust 1, 2025 | msn.comINmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7thJuly 31, 2025 | globenewswire.comINmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International ConferenceJuly 29, 2025 | globenewswire.com2BNS, INMB : INmune Bio Rebounds Sharply During After Hours Trading: What&...July 28, 2025 | benzinga.comINmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International ConferenceJuly 25, 2025 | manilatimes.netMINmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer'sJuly 4, 2025 | seekingalpha.com'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On MondayJuly 4, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025The Quiet Before the Catalyst: Vertical Aerospace's Next MoveBy Jeffrey Neal Johnson | September 9, 2025ADMA, GMDA, AXLA, INMB, and FENC Company DescriptionsADMA Biologics NASDAQ:ADMA$16.11 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$16.10 -0.01 (-0.06%) As of 09/12/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Axcella Health NASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Adherex Technologies NASDAQ:FENC$8.76 -0.27 (-2.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.79 +0.03 (+0.34%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.INmune Bio NASDAQ:INMB$2.01 +0.04 (+2.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.01 0.00 (0.00%) As of 09/12/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
